CY2126B1 - Heteroatoms-containing tricyclic compounds - Google Patents

Heteroatoms-containing tricyclic compounds

Info

Publication number
CY2126B1
CY2126B1 CY9900004A CY9900004A CY2126B1 CY 2126 B1 CY2126 B1 CY 2126B1 CY 9900004 A CY9900004 A CY 9900004A CY 9900004 A CY9900004 A CY 9900004A CY 2126 B1 CY2126 B1 CY 2126B1
Authority
CY
Cyprus
Prior art keywords
heteroatoms
tricyclic compounds
containing tricyclic
compounds
various
Prior art date
Application number
CY9900004A
Other languages
English (en)
Inventor
Karl Baumann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929209815A external-priority patent/GB9209815D0/en
Priority claimed from GB939304927A external-priority patent/GB9304927D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2126B1 publication Critical patent/CY2126B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
CY9900004A 1992-05-07 1999-02-03 Heteroatoms-containing tricyclic compounds CY2126B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929209815A GB9209815D0 (en) 1992-05-07 1992-05-07 Organic compounds,processes for their production and their use
GB939304927A GB9304927D0 (en) 1993-03-10 1993-03-10 Organic compounds

Publications (1)

Publication Number Publication Date
CY2126B1 true CY2126B1 (en) 2002-06-21

Family

ID=26300836

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9900004A CY2126B1 (en) 1992-05-07 1999-02-03 Heteroatoms-containing tricyclic compounds

Country Status (25)

Country Link
US (1) US5514685A (es)
EP (1) EP0569337B1 (es)
JP (1) JP2788392B2 (es)
KR (1) KR100292311B1 (es)
CN (1) CN1037773C (es)
AT (1) ATE155787T1 (es)
AU (1) AU668152B2 (es)
CA (1) CA2095659C (es)
CY (1) CY2126B1 (es)
CZ (1) CZ291773B6 (es)
DE (1) DE69312386T2 (es)
DK (1) DK0569337T3 (es)
ES (1) ES2105193T3 (es)
FI (2) FI102612B1 (es)
GR (1) GR3024754T3 (es)
HU (2) HUT66531A (es)
IL (1) IL105607A (es)
MY (1) MY109602A (es)
NO (1) NO305865B1 (es)
NZ (1) NZ247553A (es)
PH (1) PH30456A (es)
RU (1) RU2126009C1 (es)
SG (1) SG47011A1 (es)
SK (1) SK282061B6 (es)
TW (1) TW330936B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CN1089233C (zh) 1994-10-26 2002-08-21 诺瓦蒂斯有限公司 药物组合物
IL115742A (en) 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
BRPI9909201B8 (pt) 1998-03-26 2021-05-25 Astellas Pharma Inc formulação de composto de macrolídeo de liberação controlada
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2492989C (en) 2002-07-23 2012-11-20 Novartis Ag Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
KR100469917B1 (ko) * 2002-09-09 2005-02-02 (주)조은식품 구수한 호박씨가 첨가된 호박엿 및 그 제조방법
KR100745493B1 (ko) * 2005-12-16 2007-08-03 주식회사농심 조직감이 향상된 사출 스낵 및 그 제조 방법
EP2552923B1 (en) * 2010-04-02 2014-03-26 Janssen R&D Ireland Macrocyclic integrase inhibitors
CN107106588B (zh) 2014-10-28 2020-08-11 山口晃史 用于改善妊娠状态的药剂及其使用
CN112533599A (zh) 2018-08-10 2021-03-19 山口晃史 与母体和胎儿的关系中的体液免疫相关的疾病的治疗药
AU2019401108A1 (en) 2018-12-18 2021-07-01 Koushi Yamaguchi Agent for improving infertility, recurrent miscarriage, and state of pregnancy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP0364031B1 (en) * 1988-10-12 1992-12-23 Merck & Co. Inc. Hydroxide mediated fk-506 rearrangement process
CA1316916C (en) * 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
CA2032159A1 (en) * 1989-06-14 1990-12-15 Andrew J. F. Edmunds Heteroatoms-containing tricyclic compounds
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressive¹activity
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
WO1993004679A1 (en) * 1991-09-05 1993-03-18 Abbott Laboratories Macrocyclic immunomodulators

Also Published As

Publication number Publication date
AU3839393A (en) 1993-11-11
KR100292311B1 (ko) 2001-09-17
CZ291773B6 (cs) 2003-05-14
DK0569337T3 (da) 1998-01-19
CA2095659C (en) 2005-08-09
US5514685A (en) 1996-05-07
SK282061B6 (sk) 2001-10-08
JP2788392B2 (ja) 1998-08-20
RU2126009C1 (ru) 1999-02-10
ES2105193T3 (es) 1997-10-16
DE69312386T2 (de) 1998-01-29
JPH0641144A (ja) 1994-02-15
FI932035A0 (fi) 1993-05-05
GR3024754T3 (en) 1997-12-31
FI932035A (fi) 1993-11-08
PH30456A (en) 1997-05-28
CA2095659A1 (en) 1993-11-08
HU9301190D0 (en) 1993-07-28
KR940005631A (ko) 1994-03-22
CZ82993A3 (en) 1994-01-19
HU211135A9 (en) 1995-10-30
SK43593A3 (en) 1995-07-11
CN1083486A (zh) 1994-03-09
EP0569337A1 (en) 1993-11-10
DE69312386D1 (de) 1997-08-28
FI102612B (fi) 1999-01-15
FI102612B1 (fi) 1999-01-15
TW330936B (en) 1998-05-01
MY109602A (en) 1997-03-31
FI982476A0 (fi) 1998-11-16
IL105607A0 (en) 1993-09-22
NO931627L (no) 1993-11-08
AU668152B2 (en) 1996-04-26
NZ247553A (en) 1995-07-26
NO931627D0 (no) 1993-05-05
ATE155787T1 (de) 1997-08-15
CN1037773C (zh) 1998-03-18
IL105607A (en) 1998-01-04
NO305865B1 (no) 1999-08-09
HUT66531A (en) 1994-12-28
SG47011A1 (en) 1998-03-20
EP0569337B1 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
TW269678B (es)
SG47559A1 (en) 7-(substituted)-9-[(substituted glycl) amido]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
IL106676A0 (en) Novel 7-(substituted)-8-(substituted-9-(substituted glycyl)amido)-6-demethyl-6-deoxytetracyclines
CY2543B1 (en) 9-Ä(Substituted glycyl)amidoÜ-6-(substituted)-5-hydroxy-6-deoxytetracyclines
SG47011A1 (en) Heteroatoms-containing tricyclic compounds
HU9401582D0 (en) Maqcrolide tetrahydropyrane derivatives
GB2294927B (en) New 2,2,6,6-tetramethyl-piperidine derivatives for use as stabilizing agents for organic materials against light,heat and oxidation
TW221051B (es)
DE69313931D1 (de) Polycyclische 31668P- und 31668U-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als antibiotische oder antitumorale Arzneistoffe
GB9522273D0 (en) New 2,2,6,6-tetramethyl-piperidine derivatives for use as stabilizing agents for organic materials against light,heat and oxidation